<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336527">
  <stage>Registered</stage>
  <submitdate>12/02/2011</submitdate>
  <approvaldate>15/02/2011</approvaldate>
  <actrnumber>ACTRN12611000182998</actrnumber>
  <trial_identification>
    <studytitle>Effect of allopurinol on prevention of pancreatitis after Endoscopic Retrograde Cholangio Pancreatography(ERCP)</studytitle>
    <scientifictitle>A double blind randomized clinical trial to evaluate the effect of oral allopurinol on the prevention of post ERCP pancreatitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>pancreatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>administration of oral allopurinol 300 mg twice daily for 1 day</interventions>
    <comparator>administration of placebo tablet like allopurinol two times daily with compenent of microcellolose</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>(amylase level in plasma by using automated analyzer ,using a Kodak Ektachem 700-XR analyzer C series, normal )</outcome>
      <timepoint>10 days following ERCP</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>(duration of hospital stay due to clinical signs of pancreatitis)</outcome>
      <timepoint>10 days following ERCP</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>all patients above 20 years old undergoing ERCP in the gastrointestinal and liver diseases ward of Talighani hospital (Tehran, Iran) with informed consent</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>patients with renal failure or patients with bone marrow suppression ,those who had developed acute pancreatitis during 2 weeks before ERCP, pregnant women, patient who took azathioprine and those who didnt  agree to participate in the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation involved contacting the holder of the allocation schedule who was “off-site” or at central administration site.</concealment>
    <sequence>Simple randomisation using a randomisation table from a statistic book</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>10/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>500</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Mohammad Abbasinazari</primarysponsorname>
    <primarysponsoraddress>Department of Clinical Pharmacy, Faculty of Pharmacy,Valiasr St,Nyayesh Junction, Tehran, Iran , 1991953381</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shahid Beheshti University of Medical Sciences</fundingname>
      <fundingaddress>Department of Clinical Pharmacy, Faculty of Pharmacy,Valiasr St,Nyayesh Junction, Tehran, Iran , 1991953381</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Research center for gastroenterology and liver diseases</sponsorname>
      <sponsoraddress>Faculty of Pharmacy,Valiasr St,Nyayesh Junction, Tehran, Iran , 1991953381</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>ERCP pancreatitis is a frequent complication either for diagnosis or treatment of pancreatobiliary diseases. A number of pharmacological agents have been tried for prevention or alleviation of the complication. Allopurinol with free radical scavenger property has been considered as an effective prophylactic agent in some clinical trials. Administration of Allopurinol in these trials was done in a long period before doing ERCP. Hence Allopurinol converts to oxupurinol in the liver rapidly; it seems that clinical judgment about the net effect of Allopurinol on prevention of post ERCP pancreatitis is doubtful.Aim of present study is to determine effect of allopurinol in prevention of post ERCP pancreatitis by changing time administration of allopurinol compared with previous studies.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Shahid Beheshti university of Medical sciences ethical committee</ethicname>
      <ethicaddress>Faculty of Pharmacy,Valiasr St,Nyayesh Junction, Tehran, Iran , 1991953381</ethicaddress>
      <ethicapprovaldate>11/10/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>11/09/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mohammad Abbsinazari</name>
      <address>Department of Clinical Pharmacy, Faculty of Pharmacy,Valiasr St,Nyayesh Junction, Tehran, Iran , 1991953381</address>
      <phone>+982188873704</phone>
      <fax>+982188873704</fax>
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mohammad Abbsinazari</name>
      <address>Department of Clinical Pharmacy, Faculty of Pharmacy,Valiasr St,Nyayesh Junction, Tehran, Iran , 1991953381</address>
      <phone>+982188873704</phone>
      <fax>+982188873704</fax>
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mohammad Abbsinazari</name>
      <address>Department of Clinical Pharmacy, Faculty of Pharmacy,Valiasr St,Nyayesh Junction, Tehran, Iran , 1991953381</address>
      <phone>+982188873704</phone>
      <fax>+982188873704</fax>
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>